The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Peripheral Neuropathy Market In 2026 And 2030?
The peripheral neuropathy market size has experienced rapid expansion in recent years. It is projected to increase from $4.59 billion in 2025 to $5.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. The growth observed in the historic period stems from the high prevalence of diabetic neuropathy, rising chemotherapy use, limited targeted therapies, reliance on conventional analgesics, and the lack of early diagnosis tools.
The peripheral neuropathy market is projected to experience substantial expansion in the coming years. It is anticipated to reach $7.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.5%. This anticipated growth during the forecast period is fueled by several factors, including developments in nerve stimulation therapies, the rising acceptance of physical therapy alongside non-pharmacological interventions, a wider availability of topical and systemic medications, the increasing reliance on online pharmacies and telemedicine services, and the expansion of specialized clinics and ambulatory care facilities. Key trends expected during this period involve the greater uptake of AI-based diagnostic tools for peripheral neuropathy, enhanced integration of big data and cloud solutions for monitoring patients, the expanding application of genomics and precision medicine in treating peripheral neuropathy, increased deployment of IoT-enabled wearable devices designed for nerve health, and the growing incorporation of Industry 4.0 technologies into neuropathy treatment devices.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp
Which Primary Drivers Are Impacting The Peripheral Neuropathy Market Growth?
The increasing occurrence of diabetes is anticipated to boost the expansion of the peripheral neuropathy market in the coming years. Diabetes is a long-term medical condition marked by elevated glucose levels in the bloodstream, resulting from the body’s failure to produce or properly utilize insulin. This escalating prevalence of diabetes is mainly attributable to factors such as growing rates of obesity, inactive lifestyles, and older demographics. Peripheral neuropathy can be caused by diabetes through nerve damage from sustained high blood sugar, leading to symptoms such as discomfort, tingling sensations, and numbness in the limbs. Controlling blood sugar effectively is vital for preventing or slowing the advancement of this complication. For example, the International Diabetes Federation, a Belgium-based diabetes research organization, reported in 2024 that the global number of adults aged 20 to 79 years living with diabetes is predicted to rise substantially from approximately 589 million in 2024 to 853 million by 2050, indicating a 45% increase. Consequently, the growing incidence of diabetes is fueling the expansion of the peripheral neuropathy market.
How Is The Peripheral Neuropathy Market Segmented Across Different Segment Categories?
The peripheral neuropathy market covered in this report is segmented –
1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated), Idiopathic
2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis
3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments
4) By End-User: Hospitals, Clinics, Ambulatory Centers
Subsegments:
1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies
2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy
3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy
4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy
Which Trends Are Shaping Growth In The Peripheral Neuropathy Market?
Companies operating within the peripheral neuropathy market are prioritizing the development of sophisticated solutions, including point-of-care devices, to enhance the diagnosis and management of the condition. A point-of-care peripheral neuropathy quantitative screening test functions as a diagnostic instrument utilized for the quick identification of nerve damage in individuals’ extremities, particularly in those with diabetes. For example, in January 2023, NeuroMetrix Inc., a US-based non-invasive medical device manufacturer, unveiled the DPNCheck 2.0 point-of-care device, specifically designed for detecting peripheral neuropathy. This device employs nerve conduction technology to identify the systemic deterioration of peripheral nerves, which often contributes to severe conditions such as diabetic peripheral neuropathy (DPN). It enables swift patient screening by providing quantitative peripheral nerve function measurement, thereby establishing itself as a more efficient and precise tool when compared to conventional approaches like monofilament and tuning fork tests.
Which Organizations Play A Role In The Peripheral Neuropathy Market Landscape?
Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, Lexicon Pharmaceuticals, Johnson and Johnson, Teva Pharmaceutical Industries Ltd, Sanofi, GSK plc
Get The Full Peripheral Neuropathy Market Report:
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Which Region Leads The Peripheral Neuropathy Market In Overall Market Size?
North America was the largest region in the peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Peripheral Neuropathy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Browse Through More Reports Similar to the Global Peripheral Neuropathy Market 2026, By The Business Research Company
Tendonitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/tendonitis-treatment-global-market-report
Negative Pressure Wound Therapy Market Report
Pruritus Therapeutic Market Report
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model